Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

ClinicalTrials.gov ID: NCT02973997

Public ClinicalTrials.gov record NCT02973997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study

Study identification

NCT ID: NCT02973997
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Academic and Community Cancer Research United; Other
Enrollment: 57 participants

Conditions and interventions

Conditions

Interventions

Laboratory Biomarker Analysis Other
Lenvatinib Drug
Lenvatinib Mesylate Drug
Pembrolizumab Biological

Other · Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 6, 2018
Primary completion: Aug 14, 2022
Completion: Oct 7, 2023
Last update posted: Aug 28, 2025

2018 – 2023

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Torrance	California	90502	—
University of Colorado Hospital	Aurora	Colorado	80045	—
Massachusetts General Hospital Cancer Center	Boston	Massachusetts	02114	—
University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	48109	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	—
M D Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02973997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 28, 2025 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02973997 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →